Urigen Holdings Inc

Urigen is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen has five products in development for urology indications that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for which a Phase 2b study in on-going for the treatment of Chronic Pelvic Pain (CPP); U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting Acute Urethral Discomfort; and U302, targeting urethritis.

Contact Details: 515 West Hastings Street, Suite 7333 Vancouver, British Columbia V6B 5K3 Canada Tel: Fax: Email: herman@urigen.com WWW: www.urigen.com/

Loading...

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 198 times since April 2007, the link to the organisation's website has been followed 47 times

Recent Search Terms used to find this page: Urigen Holdings | urigen.com | urigen | urigen | urigen.com email | t | urigen.com | t | herman@urigen.com | .

Search for more companies in Vancouver,

Search for more companies in British Columbia

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Urigen Holdings Inc